Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,359.14 +5.11 (+0.10%) Dow
38,932.16 +124.83 (+0.32%) Nasdaq
17,189.10 +1.20 (+0.01%) Bitcoin USD
71,484.95 +691.51 (+0.98%) CMC Crypto 200
1,520.78 -4.02 (-0.26%)
GSK Aug 2024 39.000 put
| Previous close | 0.9000 |
| Open | 0.7500 |
| Bid | 0.0000 |
| Ask | 0.9000 |
| Strike | 39.00 |
| Expiry date | 2024-08-16 |
| Day's range | 0.5500 - 0.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 673 |
Evening StandardFTSE 100 Live 3 June: New York trading glitch sparks volatility, GSK shares tumble
GSK shares are today’s major focus after the drugs giant’s defence against Zantac claims suffered a setback in a Delaware court. The FTSE 100 index is trading higher after Friday’s late rally by Wall Street markets was further boosted by this week’s prospect of an ECB interest rate cut. Other companies in the spotlight today include FTSE 250-listed Hollywood Bowl, having posted an 11% rise in half-year profits.
BenzingaGSK's Blenrep Combo Therapy Cuts Risk Of Disease Progression Or Death By Around 50% In Pretreated Multiple Myeloma
On Sunday, GSK plc (NYSE:GSK) released results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex for relapsed or refractory multiple myeloma. The data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. On the primary endpoint of progression-free survival (PFS), the belantamab mafodotin comb
The TelegraphOil price slumps by 4pc despite Opec cuts
Oil prices have slumped nearly 4pc despite Opec production cuts amid signs that Saudi Arabia will struggle to maintain caps on future supply.
